-
Mashup Score: 3Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer - 13 day(s) ago
Sibylle Loibl, MD, PhD, of the German Breast Group, Neu-Isenburg, Germany, presented primary results of the randomized phase III PADMA trial comparing first-line endocrine therapy plus palbociclib vs standard mono-chemotherapy in women with high-risk HER2-negative/HR-positive metastatic breast cancer and indication for chemotherapy (Abstract LB1-03). Disclaimer: This video transcript has not been proofread or edited and may contain errors. The PADMA study investigated whether an endocrine-based treatment
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 14Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer - 14 day(s) ago
As reported in The New England Journal of Medicine by Andre et al, interim analysis of the phase III CheckMate 8HW trial has shown that nivolumab plus ipilimumab prolonged progression-free survival vs…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer - The ASCO Post https://t.co/MlZvcn5osg
-
-
Mashup Score: 15Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL - 14 day(s) ago
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in a population of patients with TP53 -aberrrant chronic lymphocytic leukemia (CLL). The triplet was active and well tolerated as a front-line therapy, Dr. Davids noted, and these findings support its use for such patients with high-risk CLL (Abstract 1865). Disclaimer: This video transcript has not been
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
Matthew S. Davids on Triplet Therapy of Acalabrutinib Venetoclax and Obinutuzumab Focus on TP53 Aberrant CLL - The ASCO Post https://t.co/yjlLV19vN2
-
-
Mashup Score: 10
Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, of Fred Hutch Cancer Center and the University of Washington School of Medicine, presented results of a prospective, multicenter observational study across 13 predominantly academic centers enrolling adult patients with acute myeloid leukemia. The research aimed to evaluate the potential impact of socioeconomic disparities on receipt of hematopoietic cell transplantation in patients as well as survival outcomes (Abstract 6). Disclaimer: This video transcript
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Learn about the impact of socioeconomic disparities on receipt of hematopoietic cell transplantation in this video from @ASH_hematology 2024 featuring Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc https://t.co/6NjPDaOqLI #ASH2024 #leusm #Leukemia https://t.co/cEn8RdWmdh
-
-
Mashup Score: 5
Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease by cultivating a healthy gut microbiome, according to research presented by …
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant according to study presented at @ASH_hematology 2024. https://t.co/ys0hnGOzoA #stemcell #GVHD #ASH24
-
-
Mashup Score: 3
Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He discusses how these findings could have significant implications for future microbiome-modulating therapies, leading to improved long-term outcomes (Abstract 780). Disclaimer: This video transcript has not been proofread or edited and may contain errors. Hello, my name is Erik Orberg from the University
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Watch this video interview with Erik Thiele Orberg, MD, PhD to learn about intestinal microbiome recovery following allogeneic stem cell transplantation. https://t.co/v4P3n9VVr6 #microbiome https://t.co/ZTuYaNmpoA
-
-
Mashup Score: 4Project Facilitate: 5 Years of Progress, Outreach, and Service - 15 day(s) ago
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the FDA. In this installment, the authors discuss the past 5 years of Project Facilitate, an OCE in…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
Project Facilitate: 5 Years of Progress, Outreach, and Service - The ASCO Post https://t.co/f0asnGSUnY
-
-
Mashup Score: 2Meetings - The ASCO Post - 15 day(s) ago
William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn Sage … Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October… Charles E. Geyer, Jr, MD, FACP, discusses the management of patients with HER2-positive breast cancer
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Don't miss these insights from William Gradishar, MD; Sunil S. Badve, MD; Charles E. Geyer, Jr, MD; & Frederick Howard, MD with our coverage from @lynnsage Breast Cancer Symposium 2024. Watch all 4 videos here: https://t.co/lmU3z3DhJH #bcsm #breastcancer #oncology #LSBC24 https://t.co/PEFK2S5etk
-
-
Mashup Score: 0Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma - 21 day(s) ago
Maeve Lowery, MD, discusses the results of the phase II DUBHE-H-308 trial, which evaluated QL1706—a bifunctional antibody consisting of iparomlimab and tuvonralimab—plus bevacizumab and/or chemotherapy in the first-line treatment of advanced hepatocellular carcinoma (Abstract LBA38). Disclaimer: This video transcript has not been proofread or edited and may contain errors. This presentation by Dr. Shu and colleagues reports results of a phase II study in the first-line treatment of locally advanced or
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma https://t.co/iwE9qbmgfl #hpbcsm #LiverCancer #oncology #ESMO24 #CancerInstIRE
-
-
Mashup Score: 0
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr Josep Llovet: So hepatocellular carcinoma is a major health problem globally. Is the second cause of cancer-related death, and there are around 1
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma https://t.co/w1P2ySlQQv #hpbcsm #livercancer #oncology #ESMO24 @IcahnMountSinai
-
Hear about the primary results of the Phase III PADMA study in this video featuring Sibylle Loibl, MD, PhD from the 2024 San Antonio Breast Cancer Symposium. https://t.co/oQfDvLNRJR #BreastCancer #bcsm https://t.co/brd20DTvIb